Clinical Trial Update: Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating navitoclax with abiraterone acetate, with or without hydroxychloroquine, in progressive metastatic castration-resistant prostate canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Zytiga) (abiraterone acetate)
• Hydroxychloroquine (hydroxychloroquine)
• Navitoclax (navitoclax)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-03-31